Indefinite Delivery Contract SPE2DR25D9767

The federal contract IDV award SPE2DR25D9767 is a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, which is valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

The original solicitation for this IDC is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple regional Prime Vendor contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, the United States Coast Guard, and other government agencies. The solicitation, which is expected to be issued in March 2024, will be an unrestricted, fully competitive acquisition with a total estimated value of $30.3 billion. Awards will be made on a regional basis, with at least three different contractors to be selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items.